Prices as of 2026/10/30 close
Company comparison · Major Pharmaceuticals
Astellas is the bigger company, with revenue of ¥2.1T — 4.7x Sumitomo Pharma's ¥453.3B.
Sumitomo Pharma earns more on each yen of sales, with an operating margin of 23.7% — 5.8 points above Astellas (17.9%).
Revenue growth in the latest results: Sumitomo Pharma +13.7%, Astellas +11.9%. For next year, Astellas guides for the fastest operating profit growth (+3.2%).
Astellas pays more on average — ¥10.5M against ¥9.06M at Sumitomo Pharma.
Over the past year the shares moved Astellas +63.2%, Sumitomo Pharma +13.9%.
Head-to-head wins16 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Astellas aheadAstellas 3 : Sumitomo Pharma 0
Revenue: Astellas ¥2.1T / Sumitomo Pharma ¥453.3B
ProfitabilityInvestors
Sumitomo Pharma aheadAstellas 1 : Sumitomo Pharma 2
Operating margin: Astellas 17.9% / Sumitomo Pharma 23.7%
GrowthInvestors
Astellas aheadAstellas 3 : Sumitomo Pharma 2
Revenue growth (YoY): Astellas +11.9% / Sumitomo Pharma +13.7%
Stock & balance sheetInvestors
EvenAstellas 1 : Sumitomo Pharma 1
Share price, 1 year: Astellas +63.2% / Sumitomo Pharma +13.9%
Pay & workforceJob seekers
Astellas aheadAstellas 2 : Sumitomo Pharma 1
Average salary: Astellas ¥10.5M / Sumitomo Pharma ¥9.06M
| Metric | Astellas | Sumitomo Pharma | Gap |
|---|---|---|---|
| Revenue | ◎¥2.1T | ¥453.3B | 4.7x |
| Operating profit | ◎¥382.6B | ¥107.3B | 3.6x |
| Net income | ◎¥291.5B | ¥106.9B | 2.7x |
| Metric | Astellas | Sumitomo Pharma | Gap |
|---|---|---|---|
| Operating margin | 17.9% | ◎23.7% | 5.8pt |
| Net margin | 13.6% | ◎23.6% | 9.9pt |
| Revenue per employee | ◎¥521M | ¥259M | 2.0x |
| Metric | Astellas | Sumitomo Pharma | Gap |
|---|---|---|---|
| Revenue growth (YoY) | +11.9% | ◎+13.7% | 1.8pt |
| Operating profit growth (YoY) | ◎+832.4% | +272.6% | 559.8pt |
| Revenue CAGRlast 5 years | ◎+11.4% | −2.6% | 13.9pt |
| Guidance: revenue growthnext FY plan | +3.8% | ◎+19.1% | 15.4pt |
| Guidance: op. profit growthnext FY plan | ◎+3.2% | −16.2% | 19.4pt |
| Metric | Astellas | Sumitomo Pharma | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+63.2% | +13.9% | 49.3pt |
| Share price, 3 months | +12.4% | ◎+46.0% | 33.6pt |
| Share price (close) | ¥2,571 | ¥1,884.5 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Astellas | Sumitomo Pharma | Gap |
|---|---|---|---|
| Average salary | ◎¥10.5M | ¥9.06M | ¥1.41M |
| Starting salary (monthly) | ◎¥326,700 | ¥245,000 | ¥81,700 |
| Average tenure | 15.7 yrs | ◎18.9 yrs | 3.2 |
| Average age | 42.3 | 44.5 | 2.2 |
| Employees | 4,105 | 1,747 | 2.3x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥2,571+63.2% (1Y)
Astellas +63.2% over 1Y. Compared: Sumitomo Pharma +13.9%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Astellas3 segments
Sumitomo Pharma3 segments
AAverage annual salary from the securities filings: Astellas ¥10.5M, Sumitomo Pharma ¥9.06M. Astellas pays the most. Averages also depend on staff age and job mix, so check the average age too (Astellas 42.3, Sumitomo Pharma 44.5).
ARevenue in the latest results: Astellas ¥2.1T, Sumitomo Pharma ¥453.3B. Astellas is the bigger company, with revenue of ¥2.1T — 4.7x Sumitomo Pharma's ¥453.3B.
AOperating margins: Sumitomo Pharma 23.7%, Astellas 17.9%. Sumitomo Pharma turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Astellas +63.2%, Sumitomo Pharma +13.9%. Astellas has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
